These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 24750803)
1. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. Parente P; Parnis F; Gurney H Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803 [TBL] [Abstract][Full Text] [Related]
2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
3. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ; Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782 [TBL] [Abstract][Full Text] [Related]
4. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637 [TBL] [Abstract][Full Text] [Related]
5. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956 [TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248 [TBL] [Abstract][Full Text] [Related]
7. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364 [TBL] [Abstract][Full Text] [Related]
9. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736 [TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. George DJ; Sartor O; Miller K; Saad F; Tombal B; Kalinovský J; Jiao X; Tangirala K; Sternberg CN; Higano CS Clin Genitourin Cancer; 2020 Aug; 18(4):284-294. PubMed ID: 32057714 [TBL] [Abstract][Full Text] [Related]
11. Advances in the management of castration resistant prostate cancer. Ritch CR; Cookson MS BMJ; 2016 Oct; 355():i4405. PubMed ID: 27754846 [TBL] [Abstract][Full Text] [Related]
12. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948 [TBL] [Abstract][Full Text] [Related]
14. Treatment sequencing in metastatic castrate-resistant prostate cancer. Sartor O; Gillessen S Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654 [TBL] [Abstract][Full Text] [Related]
15. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258 [TBL] [Abstract][Full Text] [Related]
16. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712 [TBL] [Abstract][Full Text] [Related]